Do Epidemiological Parameters in Patients with Localized Prostate Cancer have an Influence on whether a Patient is Envisaged for Surgery or Brachytherapy?

Table 3: Comparison of Oncological Data Between Therapy Groups

Oncological Data	Therapy Groups				Study Cohort
Oncological Data	OP/RPP	OP/RRP	BT/HDR	BT/LDR	Study Cohort
Gleason-Score (mean); n=666	6.37	6.7	6.04	4.95	6.22
Prostate volume (cm); n=555	60.42	64.08	-	-	60.93
Tumor volume (cm); n=551	5.51	7.32	-	-	5.76
PSA (ng/ml); n=785	10.69	16.26	22.76	6.53	12.03
pT-Stadium
2 (%); n=340	62.2	51.2	61.9	57.9	60.5
3 (%); n=212	36.3	45.4	-	-	37.7
4 (%); n=10	1.5	3.5	-	-	1.8
Tumor Grading
1 (%); n=36	6.1	4.9	-	40	8.2
2 (%); n=301	73	54.9	-	53.3	68.3
3 (%); n=102	21	40.2	-	-	23.1
4 (%); n=2	-	-	-	6.7	0.5
Nerve Sparing
yes (%); n=187	38	1.2	-	-	24.3
no (%); n=583	62	98.8	100	100	75.7

OP = operation; RPP = radical perineal prostatectomy; RRP = radical retropubic prostatectomy; BT = brachytherapy; HDR = high-doserate brachytherapy; LDR = low-doserate brachytherapy; PSA = prostate specific antigen.